Proneuron Biotechnologies
This article was originally published in Start Up
Executive Summary
Proneuron will develop new cell therapies and treatments for neurological disorders such as multiple sclerosis, Parkinson's diseases and Alzheimer's disease, ophthalmological disorders including anterior ischemic optic neuropathy and glaucoma, and immune disorders.
You may also be interested in...
Promised Land for Biotechnology
Israel is the hottest single country for high-tech start-ups in general, but advocates of life sciences say that additional funding specifically for biotechnology is needed. Without a strong pharmaceutical industry, Israel lacks the infrastructure necessary to nurture start-ups, for example, experienced executives to run companies.
Women's Health: Too early or Too Late?
As an industry, women's health is in its infancy. It has yet to develop beyond a collection of niche specialties in reproductive medicine and breast cancer.
EPIcyte Pharmaceutical Inc.
EPIcyte has licensed patents from the Scripps Research Institute covering new methods of human antibody production in plants that can lower costs up to 100 fold. The company is also developing proprietary products based on its technology, initially, an anti-herpes prophylactic and a contraceptive based on an anti-sperm antibody.